BOSTON, July 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on Tuesday, August 8, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2023.
The call can be accessed via teleconference at: Q1 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link:https://edge.media-server.com/mmc/p/y8b7kg5q
A replay of the conference call and webcast will be available for one year beginning on August 8, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Media Contact: | |
Josh Gitelson, Director-Global Communications | |
(781) 356-9776 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$89.22 |
| Daily Change: | -1.53 -1.69 |
| Daily Volume: | 454,955 |
| Market Cap: | US$4.570B |
August 15, 2024 August 08, 2024 July 30, 2024 June 18, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
